Domainex to expand operations in Cambridge

Domainex announces the expansion of its service business with a move to new research building with larger facilities.

Successful, Cambridge based drug discovery company, Domainex, to expand services.

Wonderful to hear stories of successful science companies in the Cambridge area.  Domainex is a contract drug discovery company currently based on the Cambridge Science Park who have announced an expansion to their service resulting in the move to a new facility at the Great Chesterford Research Park near Saffron Walden.

More information can be found in their press release below.

London, UK and Cambridge, UK, 29th October 2015 / Domainex Ltd. announced today that it is expanding all aspects of its drug discovery service business including biology, analytical chemistry and medicinal chemistry. In order to provide the infrastructure required to support this expansion Domainex has signed a long-term lease with Aviva Investors for a laboratory building at Chesterford Research Park, Cambridge. Domainex and Aviva Investors are planning to invest several million pounds in the new research building.

Eddy Littler, Chief Executive Officer of Domainex said, “We are delighted with the growth our service business has achieved over the last few years, and this year we anticipate further expansion across the range of our biology and chemistry service offerings. We are in the middle of a significant recruitment round in which we have brought a number of excellent scientists into the company”.

He went on to say “The next step in our growth is the move to our new site at Chesterford Research Park in Summer 2016: this will provide Domainex with world-class laboratories and infrastructure in which the company and its employees will grow and develop. Domainex will be moving to a 20,000 sq ft laboratory with an immediate increase in capacity of 140%. I am personally very happy with Domainex’s move to Chesterford Research Park and look forward to establishing our relationship with Aviva, and with the other biotech companies on the site”.

Keith Powell, Chairman of Domainex, said “As evidenced by our recent announcements regarding our contracts with Imperial College and Auspherix, we are continuing to develop Domainex as a high-quality research company capable of first-in-class protein expression, biochemistry, cell biology and computational and medicinal chemistry.  Putting this growth alongside our successful in-house programmes on epigenetic targets, the need for expansion space is evident; we are delighted to have found this solution at Chesterford Research Park.”

Martin Sylvester, Marketing Director with The Churchmanor Estates Company plc, joint developers of the Park with Aviva Investors, commented: “Domainex is clearly the kind of dynamic company that we are delighted to have at Chesterford Research Park and we look forward to establishing a strong, long term relationship, helping the company continue to grow and develop.  Chesterford’s excellent range of first class scientific facilities alongside well-executed central amenities, ideal for both interaction and relaxation, continues to attract established companies, such as Domainex, as well as the newer, up and coming players, the result of which is a thriving community that has world-class research at its heart.”